LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

Search

Charles River Laboratories International Inc

Slēgts

SektorsVeselības aprūpe

153.17 -4.05

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

152.86

Max

153.81

Galvenie mērījumi

By Trading Economics

Ienākumi

27M

53M

Pārdošana

48M

1B

P/E

Sektora vidējais

592.3

35.664

Peļņas marža

5.105

Darbinieki

18,700

EBITDA

37M

221M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+13.27% upside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-275M

8B

Iepriekšējā atvēršanas cena

157.22

Iepriekšējā slēgšanas cena

153.17

Ziņu noskaņojums

By Acuity

26%

74%

59 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

Charles River Laboratories International Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 12. sept. 22:41 UTC

Galvenie tirgus virzītāji

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

2025. g. 12. sept. 16:04 UTC

Galvenie tirgus virzītāji

Upexi Shares Climb on Solana Gains

2025. g. 14. sept. 23:48 UTC

Tirgus saruna

Oil Futures Mixed Amid Divergent Signals -- Market Talk

2025. g. 14. sept. 23:41 UTC

Tirgus saruna

Gold Edges Lower on Likely Technical Correction -- Market Talk

2025. g. 14. sept. 23:38 UTC

Tirgus saruna

China's Economic Activity Data May Continue Reflecting Slowdown -- Market Talk

2025. g. 14. sept. 23:13 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 14. sept. 23:13 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2025. g. 14. sept. 23:13 UTC

Tirgus saruna

Infratil May Need to Be More Aggressive With Asset Sales -- Market Talk

2025. g. 14. sept. 23:13 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 14. sept. 23:04 UTC

Tirgus saruna

Aristocrat's Interactive Unit Appears in Safe Hands -- Market Talk

2025. g. 13. sept. 08:20 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 12. sept. 20:50 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 12. sept. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 12. sept. 20:09 UTC

Peļņas

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

2025. g. 12. sept. 19:23 UTC

Tirgus saruna

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

2025. g. 12. sept. 19:16 UTC

Tirgus saruna

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

2025. g. 12. sept. 19:03 UTC

Tirgus saruna

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

2025. g. 12. sept. 18:59 UTC

Tirgus saruna

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

2025. g. 12. sept. 18:38 UTC

Tirgus saruna
Peļņas

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

2025. g. 12. sept. 18:33 UTC

Tirgus saruna

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

2025. g. 12. sept. 18:22 UTC

Tirgus saruna

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

2025. g. 12. sept. 16:56 UTC

Tirgus saruna

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

2025. g. 12. sept. 16:22 UTC

Peļņas

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

2025. g. 12. sept. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 12. sept. 16:19 UTC

Iegādes, apvienošanās, pārņemšana

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

2025. g. 12. sept. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 12. sept. 16:11 UTC

Peļņas

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

2025. g. 12. sept. 15:37 UTC

Tirgus saruna

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

2025. g. 12. sept. 15:22 UTC

Tirgus saruna

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

2025. g. 12. sept. 15:07 UTC

Iegādes, apvienošanās, pārņemšana

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Charles River Laboratories International Inc Prognoze

Cenas mērķis

By TipRanks

13.27% augšup

Prognoze 12 mēnešiem

Vidējais 173.18 USD  13.27%

Augstākais 195 USD

Zemākais 151 USD

Pamatojoties uz 13 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Charles River Laboratories International Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

13 ratings

5

Pirkt

8

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

117.16 / 144.77Atbalsts un pretestība

Īstermiņā

Strong Bullish Evidence

Vidējā termiņā

Weak Bullish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

59 / 371 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat